文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

口服阿奇霉素与磺胺多辛-乙胺嘧啶间歇性预防治疗方案对塞拉利昂儿童死亡率的影响:随机、两臂、双盲、安慰剂对照临床试验(ICARIA)试验方案

Impact of oral azithromycin and intermittent preventive treatment with sulfadoxine-pyrimethamine regimen on child mortality in Sierra Leone: trial protocol for a randomised, two-arm, double-blinded, placebo-controlled clinical trial (ICARIA).
PubMed 文献 · Trials · 2024-09-27

ICARIA是一项在塞拉利昂通过扩大免疫规划实施的III期、两臂、个体随机、双盲、安慰剂对照试验,纳入约6周龄婴儿20560例,按1:1随机接受口服阿奇霉素(20 mg/kg体重)或安慰剂,在三个时间点给药。主要结局为18月龄时全因死亡率,同时评估抗菌药物耐药性、免疫应答、安全性、SP耐药标志物流行率及可行性、可接受性。

要点

  • 在塞拉利昂通过扩大免疫规划纳入约6周龄婴儿20560例,1:1随机接受阿奇霉素或安慰剂。
  • 阿奇霉素剂量为20 mg/kg体重,分别在约6周龄、9月龄和15月龄给药。
  • 主要结局为18月龄时全因死亡率,通过死亡监测评估。

核心结论

  • 该试验将为撒哈拉以南非洲高死亡率地区采纳和大规模实施阿奇霉素提供政策所需证据。

研究设计与样本

  • ICARIA试验为III期、两臂、个体随机、双盲、安慰剂对照试验,在塞拉利昂通过扩大免疫规划实施。
  • 共纳入20560例在约6周龄首次免疫规划接触时就诊的婴儿,按1:1比例随机分配至阿奇霉素组或安慰剂组。

主要发现

  • 阿奇霉素组在三个时间点接受口服阿奇霉素20 mg/kg体重,第二剂和第三剂分别在9月龄和15月龄给予。
  • 主要结局为18月龄时通过死亡监测评估的全因死亡率。
  • 其他试验结局包括对抗菌药物耐药性的影响、对某些关键常规免疫规划免疫接种免疫应答的影响、干预措施的安全性、SP耐药标志物的流行率以及将阿奇霉素加入免疫规划方案的可行性和可接受性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Azithromycin has been shown to be beneficial in preventing infectious diseases, including malaria, infectious diarrhoea and pneumonia. A cluster randomised control trial on azithromycin MDA in children in Niger, Malawi and Tanzania found a reduction in all-cause under-five (U5) mortality in communities who received azithromycin compared to placebo. However, the reduction was largest and statistically significant only in Niger. The purpose of this trial is to evaluate the impact of azithromycin plus intermittent preventive treatment in infants (IPTi), recently renamed by the World Health Organisation as perennial malaria chemoprevention (PMC), with sulfadoxine-pyrimethamine (SP) on all-cause mortality up to 18 months of age in children living in areas of high mortality burden through the Expanded Program on Immunisation (EPI) in Sierra Leone. METHODS: The Improving Care through Azithromycin Research for Infants in Africa (ICARIA) trial is a phase III two-arm, individually randomised, double-blinded, placebo-controlled trial administering oral AZI (20 mg/kg bodyweight) at three time points to children attending EPI visits in Sierra Leone. A total of 20,560 infants attending the first EPI contact at around 6 weeks of age are recruited and randomised to AZI or placebo in a 1:1 ratio. The second and third AZI/placebo doses are given at 9 and 15 months of age. The primary outcome of the trial is all-cause mortality rate at 18 months of age assessed through mortality surveillance. Other trial outcomes include the impact on antimicrobial resistance, and on the immune response to certain key routine EPI immunisations, the safety of the intervention, the prevalence of SP resistance markers and the feasibility, and acceptability of adding AZI to the EPI programme. DISCUSSION: The trial will provide the evidence needed to inform policy regarding the adoption and large-scale implementation of AZI in areas of high-mortality burden in sub-Saharan Africa. TRIAL REGISTRATION: ClinicalTrials.gov NCT04235816. Registered on 22 January 2020. Pan-African Clinical Trials Registry PACTR202004540256535. Registered on 14 April 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Owusu-Kyei K, Chen H, Chileshe M, et al. Impact of oral azithromycin and intermittent preventive treatment with sulfadoxine-pyrimethamine regimen on child mortality in Sierra Leone: trial protocol for a randomised, two-arm, double-blinded, placebo-controlled clinical trial (ICARIA). Trials. 2024. PMID: 39334260. doi:10.1186/s13063-024-08443-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。